Preclinical evaluation of lentiviral gene therapy for adenosine deaminase 2 deficiency (DADA2): engraftment efficiency and biodistribution in humanised NBSGW mice

by Biotech Newsroom


Patient samples

This study was approved by the Bloomsbury Ethics Committee (no. 08H071382). CD34 + HSC were obtained from the bone marrow of a 3-month-old severe DADA2 patient presenting with Pure Red-Cell Aplasia (PRCA) (genotype ADA2 p.G47W/p.G47W). Healthy donor HSC were obtained from leukapheresis provided from the Antony Nolan laboratories with consent (no. CGT125, 2 healthy donors: age 21 and 31 years old, one male, one female).

Mice

NBSGW mice were obtained from the Jackson Laboratory. Procedures were approved by the UCL Biological…



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC